Boehringer Ingelheim Corp

Codexis is one of the leaders in the development of innovative bio-based solutions for pharmaceutical chemical process development and manufacturing. The company s unique protein and strain engineering technology platform creates superior biological catalysts either enzymes or fermentation strains crafted specifically for cutting-edge chemical processes that can enable pharmaceutical process development, shorten process development timelines and dramatically improve existing manufacturing processes. Codexis has more than 12 strategic alliances, including a major collaboration with Pfizer, and more than 20 products and processes in development internally and at leading worldwide life sciences companies. It began operations as an independent company in 2002. Codexis is headquartered in Redwood City, Calif.

Hoffmann-La Roche, also known as Roche, is prescription drug unit that provides more than 35 medications in the United States in therapeutic areas, including dermatology, oncology, transplantation, AIDS, central nervous system disorders, and cardiovascular and infectious diseases. It offers products that include Accutane, Boniva, CellCept, Copegus, Cytovene, Demadex EC-Naprosyn, Romazicon, Tamiflu, Ticlid, Valcyte, Valium, Xeloda, Xenical and Zenapax. The company operates over five research centers in New Jersey and California in the United States, as well as Switzerland, Germany and China. Hoffmann-La Roche works with a team of nearly 5,000 employees. It is a part of Roche Group, which is one of the world's leading research-oriented health care groups with core businesses in pharmaceuticals and diagnostics. Operational for more than 100 years, the parent company develops a range of products and services that address prevention, diagnosis and treatment of diseases.